MedGenome acquires Illumina's NovaSeq X Plus and Launches Genome Sequencing Test KaryoSeq

News provided by

Jul 11, 2023, 01:55 ET

Becomes the first company to bring Illumina's revolutionary Genome Sequencing Technology to South Asia

Launches KaryoSeq to detect genome abnormalities in Prenatal and newborn conditions

FOSTER CITY, Calif., July 11, 2023 /PRNewswire/ -- MedGenome, a leading global Genomic Diagnostic and Research Services company in South Asia, becomes the first to offer advanced genomics services using Illumina's NovaSeq X Plus in South Asia. With this, the company anticipates bringing down the reagent cost of Human Whole Genome sequencing to USD $200 in the near future. In conjunction with this acquisition, MedGenome is thrilled to launch KaryoSeq (or Karyotype Sequencing), an innovative Whole Genome Sequencing to diagnose prenatal and newborn conditions.

The NovaSeq X Series is Illumina's most powerful sequencing system. With the ability to generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers at shorter turnaround time, this latest sequencer is aimed at making genomics more sustainable and accessible to more people globally. MedGenome has had a long-standing partnership with Illumina over the last decade expanding its portfolio of sequencing equipment with the latest offerings and becoming leaders in adopting the most up to date sequencing technology. NovaSeq X Plus promises to accelerate a deeper understanding of genetic disorders and can perform a broad range of data-intensive applications, bringing more breakthroughs genetic disease diagnosis and treatment.

MedGenome has launched several breakthrough tests in key disease areas in the last few years. The latest offering, KaryoSeq has significant advantages over traditional cytogenetic and molecular techniques. The test is a faster and accurate solution which allows for the detection of small chromosomal abnormalities, such as microdeletions or microduplications, that may not be easily identified through microscopic examination alone. It is recommended for individuals with suspected or confirmed genetic disorders or an increased risk of carrying chromosomal abnormalities, aiming to provide precise and rapid results, and helping clinicians and families make informed decisions about inherent genetic conditions.

Dr Vedam Ramprasad, PhD, CEO, MedGenome said, "As pioneers in genetic testing with deep focus on scientific innovation and research, bringing NovaSeq X Plus in India will help us in making faster and accurate diagnosis. The launch of KaryoSeq further marks a significant milestone in the field of prenatal and newborn genetic testing in this part of the world, empowering clinicians with accurate and comprehensive genetic information. Traditionally, cost has played a major factor in penetrating the genetic testing market. MedGenome has been striving to make these tests affordable to the masses while adhering to global quality standards. MedGenome's KaryoSeq test is another step in this direction. The test is cost-effective while providing superior diagnostic yield and accuracy in identifying deletions and gains as small as 1 megabase (1 million DNA base pairs)."

MedGenome offers an extensive range of over 1300 advanced genetic tests covering various disease categories. With a CAP-accredited genetic testing laboratory in India and a high-throughput Next-Generation Sequencing lab in Foster City, California, the company has established itself as a prominent player in the field. Notably, MedGenome has developed the largest database of South Asian genetic variants through its expertise in genetic diagnostics, research collaborations, and its role as a co-founding member of GenomeAsia 100K. Serving more than 3,50,000 families through a network of over 4,000 hospitals and over 11,000 clinicians across India, MedGenome provides comprehensive genetic testing services and making significant contributions to the field of genomics and continues to revolutionize the healthcare space with its path-breaking genomics solutions.

About MedGenome:

MedGenome (www.medgenome.com) is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, infectious diseases, reproductive health, and rare diseases. MedGenome has facilities across the US, India, and Singapore. Its high-throughput Next-Generation Sequencing lab in Foster City, California, supports biomarker identification and target discovery research projects for biopharma and academic institutions in the US, Europe and Canada. MedGenome is a market leader in genetic diagnostic testing in India and developed genomic datasets based on South Asian population data, algorithms, and tools to correlate genomic data with clinical and phenotypic information to provide deep insight into complex diseases at a genetic and molecular level to support drug development and personalized medicine programs.

Media Contacts:

Namrata Sharma
+91-90354 72440
Senior Manager, GCI Health
[email protected]

Debarati Das
+91-99536 57513
PR Manager, MedGenome
[email protected]

Logo: https://mma.prnewswire.com/media/2151304/MedGenome_Logo.jpg

SOURCE MedGenome